Scientists at Duke University Medical Center, the University of North Carolina, and the biotech MacroGenics have teamed up to design a molecule with the capacity to bind HIV-infected cells and unite them with the immune system's killer T cells.
In June, a team from The Scripps Research Institute in La Jolla, CA, met with federal regulators to discuss human trials for its investigational HIV vaccine. Now, researchers from the Scripps campus in Florida have won a four-year grant of up to $6 million from the Bill & Melinda Gates Foundation to develop a vaccine for HIV/AIDS that researchers there have been working on.
Some heavy-hitting HIV activists have signed on to Janssen's ongoing "Wisdom" campaign, headlining a share-your-story campaign for people living with the disease.
Caltech investigators have identified a broadly neutralizing antibody that may be particularly effective in thwarting HIV.
Bio-Rad Laboratories snagged FDA approval for its next-generation HIV Ag-Ab test for early detection of the virus. The Hercules, CA-based company's BioPlex 2200 HIV Ag-Ab assay distinguishes between HIV-1 and HIV-2 markers in human blood samples, making it the first diagnostic approved by the agency that can differentiate the infections.
Diagnostic assays that usually require a desktop reader that costs several thousand dollars can now be done using a 3-D printed plate that attaches to a smartphone. Even better, the accuracy of the results achieved are comparable to standard laboratory equipment.
Swedish biotech outfit Cavidi snagged a €10 million ($11 million) loan from the European Investment Bank to develop its next-generation automated testing device for HIV.
The search for an HIV vaccine has been long and difficult, but researchers from Johnson & Johnson, Harvard and other groups may have made a leap. J&J's Janssen reported encouraging results Thursday from its preclinical trial of an HIV vaccine in rhesus monkeys. Encouraging enough for the company to sponsor human studies--the first time a Big Pharma is doing so in the HIV space.
A team of collaborators drawn from Harvard, Johnson & Johnson and other groups published results from a preclinical animal study Thursday afternoon that underscores the potential for developing the world's first HIV vaccine.
The Centers for Disease Control and Prevention says that a formulation of Endo's pain med, Opana ER--that's supposed to be difficult to crush--is responsible for an outbreak of HIV in southern Indiana, because the changes made it easier to prepare the drug for more dangerous intravenous or subcutaneous injection.